Patents by Inventor Chantal Carrez
Chantal Carrez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210292423Abstract: The present invention concerns antibody-like binding protein specifically binding to CD3 and binding specifically to at least one further antigen, for example CD123. The present invention also concerns antibody-like binding protein specifically binding to CD123 and binding specifically to at least one further antigen. The invention further concerns anti-CD3 antibodies and anti-CD123 antibodies. The invention also relates to pharmaceutical compositions comprising the antibody-like binding protein, anti-CD3 antibodies or anti-CD123 antibodies of the invention, and their use to treat cancer. The invention further relates to isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibody-like binding protein, anti-CD3 or anti-CD123 antibody and the use of said anti-CD123 antibody as a diagnostic tool.Type: ApplicationFiled: January 12, 2021Publication date: September 23, 2021Inventors: Jana Albrecht, Cédric Barriere, Christian Beil, Jochen Beninga, Chantal Carrez, Stéphane Guerif, Katja Kroll, Christian Lange, Cendrine Lemoine, Wulf-Dirk Leuschner, Ercole Rao, Marion Schneider, Marie-Cécile Wetzel, Peter Wonerow
-
Patent number: 10906978Abstract: The present invention concerns antibody-like binding protein specifically binding to CD3 and binding specifically to at least one further antigen, for example CD123. The present invention also concerns antibody-like binding protein specifically binding to CD123 and binding specifically to at least one further antigen. The invention further concerns anti-CD3 antibodies and anti-CD123 antibodies. The invention also relates to pharmaceutical compositions comprising the antibody-like binding protein, anti-CD3 antibodies or anti-CD123 antibodies of the invention, and their use to treat cancer. The invention further relates to isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibody-like binding protein, anti-CD3 or anti-CD123 antibody and the use of said anti-CD123 antibody as a diagnostic tool.Type: GrantFiled: April 2, 2018Date of Patent: February 2, 2021Assignee: SANOFIInventors: Jana Albrecht, Cédric Barriere, Christian Beil, Jochen Beninga, Chantal Carrez, Stéphane Guerif, Katja Kroll, Christian Lange, Cendrine Lemoine, Wulf-Dirk Leuschner, Ercole Rao, Marion Schneider, Marie-Cécile Wetzel, Peter Wonerow
-
Publication number: 20180222987Abstract: The present invention concerns antibody-like binding protein specifically binding to CD3 and binding specifically to at least one further antigen, for example CD123. The present invention also concerns antibody-like binding protein specifically binding to CD123 and binding specifically to at least one further antigen. The invention further concerns anti-CD3 antibodies and anti-CD123 antibodies. The invention also relates to pharmaceutical compositions comprising the antibody-like binding protein, anti-CD3 antibodies or anti-CD123 antibodies of the invention, and their use to treat cancer. The invention further relates to isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibody-like binding protein, anti-CD3 or anti-CD123 antibody and the use of said anti-CD123 antibody as a diagnostic tool.Type: ApplicationFiled: April 2, 2018Publication date: August 9, 2018Inventors: Jana Albrecht, Cédric Barriere, Christian Beil, Jochen Beninga, Chantal Carrez, Stéphane Guerif, Katja Kroll, Christian Lange, Cendrine Lemoine, Wulf-Dirk Leuschner, Ercole Rao, Marion Schneider, Marie-Cécile Wetzel, Peter Wonerow
-
Publication number: 20180057597Abstract: The present invention concerns antibody-like binding protein specifically binding to CD3 and binding specifically to at least one further antigen, for example CD123. The present invention also concerns antibody-like binding protein specifically binding to CD123 and binding specifically to at least one further antigen. The invention further concerns anti-CD3 antibodies and anti-CD123 antibodies. The invention also relates to pharmaceutical compositions comprising the antibody-like binding protein, anti-CD3 antibodies or anti-CD123 antibodies of the invention, and their use to treat cancer. The invention further relates to isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibody-like binding protein, anti-CD3 or anti-CD123 antibody and the use of said anti-CD123 antibody as a diagnostic tool.Type: ApplicationFiled: July 20, 2017Publication date: March 1, 2018Inventors: Jana ALBRECHT, Cédric BARRIERE, Christian BEIL, Jochen BENINGA, Chantal CARREZ, Stéphane GUERIF, Katja KROLL, Christian LANGE, Cendrine LEMOINE, Wulf-Dirk LEUSCHNER, Ercole RAO, Marion SCHNEIDER, Marie-Cécile WETZEL, Peter WONEROW
-
Publication number: 20140199300Abstract: A combination of an anti-CD19 maytansinoid immunoconjugate and rituximab is used for treating CD19+CD20+ B-cell malignancies symptom, in particular Non-Hodgkin's lymphoma.Type: ApplicationFiled: July 27, 2012Publication date: July 17, 2014Applicant: SANOFIInventors: Laurent Besret, Chantal Carrez, Sandrine Payrard
-
Patent number: 8034939Abstract: This invention relates to isoindole derivates of Formula I to pharmaceutical compositions comprising such derivatives, and to methods of treatment comprising administering of such derivatives.Type: GrantFiled: September 28, 2007Date of Patent: October 11, 2011Assignee: Aventis Pharma S.A..Inventors: Patrick Mailliet, Luc Bertin, Didier Benard, Chantal Carrez, François Vallee, Eric Bacque
-
Patent number: 7943616Abstract: The invention is directed to physiologically active compounds of general formula (I):— and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.Type: GrantFiled: November 23, 2004Date of Patent: May 17, 2011Assignee: Aventis Pharmaceuticals Inc.Inventors: Paul J. Cox, Tahir N. Majid, Justine Yeun Quai Lai, Andrew D. Morley, Shelley Amendola, Stephanie D. Deprets, Christopher Edlin, Charles J. Gardner, Dorothea Kominos, Brian L. Pedgrift, Frank Halley, Timothy A. Gillespy, Michael Edwards, Francois F. Clerc, Conception Nemecek, Olivier Houille, Dominique Damour, Herve Bouchard, Daniel N. A. Bezard, Chantal Carrez
-
Patent number: 7674795Abstract: This invention relates to derivatives of 4-(benzimidazol-2-yl)fluorene and 4-(azabenzimidazol-2-yl)fluorene, to pharmaceutical compositions comprising such derivatives, and to methods of treatment of disorders related to Hsp90 protein activity, comprising administering such derivatives.Type: GrantFiled: November 14, 2007Date of Patent: March 9, 2010Assignee: Aventis Pharma SAInventors: Patrick Mailliet, Luc Bertin, Fabienne Thompson, Jean-Marie Ruxer, Fabienne Pilorge, Didier Benard, Hervé Minoux, Chantal Carrez, Hélène Goulaouic, Thierry Gouyon
-
Publication number: 20080153837Abstract: This invention relates to derivatives of 4-(benzimidazol-2-yl)fluorene and 4-(azabenzimidazol-2-yl)fluorene, to pharmaceutical compositions comprising such derivatives, and to methods of treatment of disorders related to Hsp90 protein activity, comprising administering such derivatives.Type: ApplicationFiled: November 14, 2007Publication date: June 26, 2008Applicant: AVENTIS PHARMA S.A.Inventors: Patrick MAILLIET, Luc BERTIN, Fabienne THOMPSON, Jean-Marie RUXER, Fabienne PILORGE, Didier BENARD, Herve MINOUX, Chantal CARREZ, Helene GOULAOUIC, Thierry GUYON
-
Publication number: 20080119507Abstract: This invention relates to isoindole derivates of Formula I to pharmaceutical compositions comprising such derivatives, and to methods of treatment comprising administering of such derivatives.Type: ApplicationFiled: September 28, 2007Publication date: May 22, 2008Applicant: Aventis Pharma S.A.Inventors: Patrick MAILLIET, Luc BERTIN, Didier BENARD, Chantal CARREZ, Francois VALLEE, Eric BACQUE
-
Publication number: 20080119467Abstract: Purine derivatives of formula (IA1) or (IB1), compositions containing them and use thereof as medicinal products, in particular in oncology, are describedType: ApplicationFiled: July 5, 2007Publication date: May 22, 2008Applicant: AVENTIS PHARMA S.A.Inventors: Chantal CARREZ, Florence FASSY, Patrick MAILLIET, Fabienne THOMPSON
-
Publication number: 20080108612Abstract: This invention relates to methods of inhibiting the Hsp90 chaperone protein, and methods of treatment comprising administration of compounds of formula (IA) (IB) and (II)Type: ApplicationFiled: July 5, 2007Publication date: May 8, 2008Applicant: AVENTIS PHARMA S.A.Inventors: Chantal CARREZ, Florence FASSY, Patrick MAILLIET
-
Publication number: 20080070960Abstract: This invention relates to 3-aryl-1,2-benzisoxazole derivatives of formula (I) to pharmaceutical compositions comprising such derivatives, and to methods of treatment comprising administering of such derivatives.Type: ApplicationFiled: August 20, 2007Publication date: March 20, 2008Applicant: AVENTIS PHARMA S.A.Inventors: Luc BERTIN, Chantal CARREZ, Fabienne THOMPSON, Patrick MAILLIET, Jean-Marie RUXER
-
Patent number: 7041668Abstract: The present invention discloses and claims benzimidazole compounds of formula (I): in which A is aryl or heteroaryl; R1 is selected from optionally substituted alkyl, alkoxy, aryl or heteroaryl, NH-lower alkyl or NH-cycloalkyl, or halogen, NH2; 1-imidazolyl or SO2Me; R2 is selected from optionally substituted —CO-alkyl, —CO-cycloalkyl, —CO-aralkyl, —CO-aryl, —CO-alkoxy, aryl or aralkyl, or —CO-amino, CO—NHR3 or CO—R3R4 wherein R3 and R4 are selecteded independently from hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, fluoroalkyl, alkynyl, heteroalkyl, alkylheteroalkyl, aryl, aralkyl or together form an alkylene chain optionally containing one to 4 heteroatoms; a pharmaceutically acceptable salt or a prodrug thereof; the use of compounds of formula (I) for the treatment of cancer, and pharmaceutical compositions comprising a compound of formula (I) and one or more pharmaceutically acceptable adjuvants or diluents.Type: GrantFiled: March 25, 2004Date of Patent: May 9, 2006Assignee: Aventis Pharma S.A.Inventors: Francois Clerc, Francois Hamy, Isabelle Depaty, Odile Angouillant-Boniface, Stéphanie Deprets, Chantal Carrez, Manfred Roesner
-
Publication number: 20050267304Abstract: The invention is directed to physiologically active compounds of general formula (I):— and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.Type: ApplicationFiled: November 23, 2004Publication date: December 1, 2005Applicant: AVENTIS PHARMACEUTICALS INC.Inventors: Paul Cox, Tahir Majid, Justine Lai, Andrew Morley, Shelley Amendola, Stephanie Deprets, Christopher Edlin, Charles Gardner, Dorothea Kominos, Brian Pedgrift, Frank Halley, Timothy Gillespy, Michael Edwards, Francois Clerc, Conception Nemecek, Olivier Houille, Dominique Damour, Herve Bouchard, Daniel Bezard, Chantal Carrez
-
Patent number: 6897207Abstract: The invention is directed to physiologically active compounds of general formula (I): and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.Type: GrantFiled: June 21, 2002Date of Patent: May 24, 2005Assignee: Aventis Pharmaceuticals Inc.Inventors: Paul J. Cox, Tahir N. Majid, Justine Yeun Quai Lai, Andrew D. Morley, Shelley Amendola, Stephanie D. Deprets, Christopher Edlin, Charles J. Gardner, Dorothea Kominos, Brian L. Pedgrift, Frank Halley, Timothy A. Gillespy, Michael Edwards, Francois F. Clerc, Conception Nemecek, Olivier Houille, Dominique Damour, Herve Bouchard, Daniel N. A. Bezard, Chantal Carrez
-
Publication number: 20050014811Abstract: The present invention discloses and claims benzimidazole compounds of formula (I): in which A is aryl or heteroaryl; R1 is sleceted from optionally substituted alkyl, alkoxy, aryl or heteroaryl, NH-lower alkyl or NH-cycloalkyl, or halogen, NH2; 1-imidazolyl or SO2Me; R2 is selected from optionally substituted —CO-alkyl, —CO-cycloalkyl, —CO-aralkyl, —CO-aryl, —CO-alkoxy, aryl or aralkyl, or —O-amino, CO—NHR3 or CO—R3R4 wherein R3 and R4 are selecteded independently from hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, fluoroalkyl, alkynyl, heteroalkyl, alkylheteroalkyl, aryl, aralkyl or together form an alkylene chain optionally containing one to 4 heteroatoms; a pharmaceutically acceptable salt or a prodrug thereof; the use of compounds of formula (I) for the treatment of cancer, and pharmaceutical compositions comprising a compound of formula (I) and one or more pharmaceutically acceptable adjuvants or diluents.Type: ApplicationFiled: March 25, 2004Publication date: January 20, 2005Applicant: Aventis Pharma S.A.Inventors: Francois Clerc, Francois Hamy, Isabelle Depaty, Odile Angouillant-Boniface, Stephanie Deprets, Chantal Carrez, Manfred Roesner
-
Publication number: 20040053931Abstract: The invention is directed to physiologically active compounds of general formula (I):— 1Type: ApplicationFiled: June 21, 2002Publication date: March 18, 2004Inventors: Paul J. Cox, Tahir N. Majid, Justine Yeun Quai Lai, Andrew D. Morley, Shelley Amendola, Stephanie D. Deprets, Christopher Edlin, Charles J. Gardner, Dorothea Kominos, Brian L. Pedgrift, Frank Halley, Timothy A. Gillespy, Michael Edwards, Francois F. Clerc, Conception Nemecek, Olivier Houille, Dominique Damour, Herve Bouchard, Daniel N.A. Bezard, Chantal Carrez